185 related articles for article (PubMed ID: 28257659)
1. Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein.
Lu J; Zhang Y; Sun M; Liu M; Wang X
Phytomedicine; 2017 Mar; 26():1-10. PubMed ID: 28257659
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp.
Li X; Hu J; Wang B; Sheng L; Liu Z; Yang S; Li Y
Toxicol Appl Pharmacol; 2014 Mar; 275(2):163-75. PubMed ID: 24380838
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
4. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
5. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
Zhang W; Tan TM; Lim LY
Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
[TBL] [Abstract][Full Text] [Related]
6. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
[TBL] [Abstract][Full Text] [Related]
7. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
[TBL] [Abstract][Full Text] [Related]
8. Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism.
Shang H; Wang Z; Ma H; Sun Y; Ci X; Gu Y; Liu C; Si D
Pharm Biol; 2021 Dec; 59(1):200-208. PubMed ID: 33595422
[TBL] [Abstract][Full Text] [Related]
9. Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein.
McEneny-King A; Edginton AN; Rao PP
Bioorg Med Chem Lett; 2015 Jan; 25(2):297-301. PubMed ID: 25499431
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using felodipine and hesperetin in combination in Wistar rats and everted rat gut sacs in vitro.
Sridhar V; Surya Sandeep M; Ravindra Babu P; Naveen Babu K
Phytother Res; 2014 May; 28(5):699-705. PubMed ID: 23881850
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Oral Bioavailability of Diltiazem by the Influence of Gallic Acid and Ellagic Acid in Male Wistar Rats: Involvement of CYP3A and P-gp Inhibition.
Athukuri BL; Neerati P
Phytother Res; 2017 Sep; 31(9):1441-1448. PubMed ID: 28766866
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
Yalkinoglu Ö; Becker A; Krebs-Brown A; Vetter C; Lüpfert C; Perrin D; Heuer J; Biedert H; Hirt S; Bytyqi A; Bachmann A; Strotmann R
Invest New Drugs; 2023 Aug; 41(4):596-605. PubMed ID: 37415001
[TBL] [Abstract][Full Text] [Related]
13. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
15. A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability.
Tan W; Chen H; Zhao J; Hu J; Li Y
J Pharm Pharm Sci; 2008; 11(3):97-105. PubMed ID: 18801310
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the roles of P-glycoprotein and cytochrome P450 in triptolide-induced liver toxicity in sandwich-cultured rat hepatocyte model.
Zhuang XM; Shen GL; Xiao WB; Tan Y; Lu C; Li H
Drug Metab Dispos; 2013 Dec; 41(12):2158-65. PubMed ID: 24065861
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
[TBL] [Abstract][Full Text] [Related]
18. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
Choi SJ; Shin SC; Choi JS
Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
[TBL] [Abstract][Full Text] [Related]
19. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.
Zhao G; Huang J; Xue K; Si L; Li G
Eur J Pharm Sci; 2013 Nov; 50(3-4):429-39. PubMed ID: 23981337
[TBL] [Abstract][Full Text] [Related]
20. The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices.
Li M; de Graaf IA; Siissalo S; de Jager MH; van Dam A; Groothuis GM
Drug Metab Dispos; 2016 May; 44(5):683-91. PubMed ID: 26932816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]